# US 2013/0280233 A1 · Cbp/catenin antagonists for enhancing asymmetric division of somatic stem cells > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2013/0280233 A1 - Document ID: US20130280233A1 - Status: Published application - Kind: A1 - Application number: 13/895,220 - Filed: 2013-05-15 - Published: 2013-10-24 - Earliest claimed: 2010-11-16 - Assignees: University of Southern California - Applicants: University of Southern California - Inventors: Michael Kahn; Jia-Ling Teo; Michael McMillan; Yi Zhao; Yongfeng Wu - Web page: https://patentgrep.com/patent/US20130280233A1 ## CPC - A61K 31/519: ortho- or peri-condensed with heterocyclic rings - A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol - A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine - A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems - A61K 31/506: not condensed and containing further heterocyclic rings - A61K 31/5575: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha - A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone - A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048}) - A61K 38/50: acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants - A61P 9/00: Drugs for disorders of the cardiovascular system - A61P 17/00: Drugs for dermatological disorders - A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like - A61P 17/06: Antipsoriatics - A61P 17/14: for baldness or alopecia - A61P 17/16: Emollients or protectives, e.g. against radiation - A61P 17/18: Antioxidants, e.g. antiradicals (preparations for protection against sunlight A61Q17/00) - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61P 31/12: Antivirals - A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - C07D 487/04: Ortho-condensed systems - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08) ## Abstract Provided are: methods for treating aging or an age-related condition, symptom or disease; methods for stimulating hair growth, regrowth or pigmentation (or preventing hair loss); methods for increasing the expression of an adenosine receptor in dermal cells (in combination with hair growth); methods for treating a condition or disease of the skin or at least one symptom thereof, including cosmetic treatment (e.g., wrinkles, hyperpigmentation, redness, rosacea, dryness, cracking, loss of firmness, loss of elasticity, thinning, and loss of vibrance). The methods comprise administering a sufficient amount of a CBP/catenin (e.g., CBP/β-catenin) antagonist as disclosed, and particularly wherein administration is in an amount and manner sufficient to provide for increasing the number of asymmetric renewing divisions relative to, or at the expense of symmetric divisions in relevant somatic stem cell population. In particular aspects, the CBP/catenin (e.g., CBP/β-catenin) antagonist comprises an alkyl and/or fatty acid ester derivative thereof as disclosed herein. ## Claims ### Claim 1 A method for treating aging or an age-related condition, symptom or disease, comprising: identifying a mammalian subject having somatic stem cells for least one tissue compartment or type having an age-related condition, symptom or disease; and administering to the subject a CBP/catenin antagonist in a manner and amount sufficient to provide for increasing the number of asymmetric renewing divisions relative to, or at the expense of symmetric divisions of the somatic stem cells for the at least one tissue compartment or type, wherein the age related condition, symptom or disease of the tissue compartment or type is decreased or ameliorated, wherein a method for treating aging or an age-related condition, symptom or disease is afforded. ### Claim 2 (depends on 1) The method of claim 1, wherein the somatic stem cells for the at least one tissue compartment or type comprise quiescent somatic stem cells, and wherein administering the CBP/catenin antagonist comprises CBP/catenin antagonist-mediated activation of the quiescent somatic stem cells to enhance or accelerate asymmetric renewing divisions relative to, or at the expense of symmetric divisions among the somatic stem cells of the at least one tissue compartment or type. ### Claim 3 (depends on 1) The method of claim 1, wherein the somatic stem cells comprise at least one selected from the stem cell group consisting of skin including keratinocyte stem cells, epidermal, follicular, hematopoietic, mammary, intestinal epithelium including crypt cells, mesenchymal including muscle satellite cells, melanocyte stem cells, osteoblasts and chondrocyte progenitors, endothelial, neural, including either the ependymal or the subventricular zone cells, neural crest, olfactory, testicular, uterine, and cuticle stem cells (e.g., finger and toe nails). ### Claim 4 (depends on 1) The method of claim 1, wherein the somatic stem cells for the at least one tissue compartment or type, comprise hair follicle stem cells of a skin tissue compartment, and wherein increased hair growth or hair pigmentation is provided at the skin tissue compartment or type, preferably at the scalp or eye lid tissue compartment or type. ### Claim 5 (depends on 4) The method of claim 4, wherein the CBP/catenin antagonist is present in an amount sufficient to modulate or increase the expression of an adenosine receptor in dermal cells, preferably dermal papilla cells. ### Claim 6 (depends on 5) The method of claim 5, wherein the adenosine receptor is at least one selected from A1, A2A, and A2B. ### Claim 7 (depends on 4) The method of claim 4, wherein the CBP/catenin antagonist is present in an amount sufficient to modulate or increase the expression of sulfonylurea receptor 2B in dermal cells, preferably dermal papilla cells. ### Claim 8 (depends on 4) The method of claim 4, comprising co-administration of or adjunct treatment with at least one other hair growth stimulating agent, or hair loss preventing agent. ### Claim 9 (depends on 8) The method of claim 8, wherein the at least one other hair growth stimulating agent is at least one selected from the group consisting of minoxidil, finasteride, dutasteride, bimatoprost and antiandrogen receptor blockers including fluridil. ### Claim 10 (depends on 1) The method of claim 1, wherein the somatic stem cells for the at least one tissue compartment or type, comprise skin stem cells of a skin tissue compartment or type, and wherein enhanced skin repair and/or homeostatic maintenance is provided at the skin tissue compartment or type. ### Claim 11 (depends on 10) The method of claim 10, comprising enhanced skin repair and/or homeostatic maintenance relating to at least one age-related condition, symptom or disease selected from the group consisting of skin conditions including wrinkles, hyperpigmentation, redness, rosacea, dryness, cracking, loss of firmness, loss of elasticity, thinning, loss of vibrance, wounds, scars, acne, sun damage, latent viral infection (e.g., to HSV, HPV) optionally in combination with an antiviral agent (e.g., docosanol, acyclovir, etc.), ulcers including diabetic ulcers, burns, atopic dermatitis, psoriasis, and hair loss or loss of hair coloration/pigmentation. ### Claim 12 (depends on 11) The method of claim 11, comprising treating a wound comprising treating to decrease scarring in the wound to the surface tissue, wherein scarring is reduced. ### Claim 13 (depends on 11) The method of claim 11, wherein treating comprises accelerating epidermal or dermal layering. ### Claim 14 (depends on 11) The method of claim 11, wherein treating increases cellular migration of at least one type of cell to the wound. ### Claim 15 (depends on 14) The method of claim 14, wherein the type of cellular migration or proliferation comprises at least one cell selected from the group consisting of: keratinocytes, fibroblasts, epidermal cells, dermal cells, epithelial cells, mast cells, neutrophils, lymphocytes, and macrophages. ### Claim 16 (depends on 11) The method of claim 11, wherein treating accelerates neoangiogenesis of blood vessels or lymphatic vessels. ### Claim 17 (depends on 11) The method of claim 11, wherein treating increases collagen deposition at the wound. ### Claim 18 (depends on 11) The method of claim 11, comprising treating a wound to a surface tissue or a symptom thereof of at least one wound type selected from the group consisting of lacerations, abrasions, rupture, puncture wounds, chemical, thermal, or radiation-induced burns, cuts, scrapes, incisions, blisters, diabetic ulcers, bedsores or pressure ulcers, skin grafts, and surgical wounds. ### Claim 19 (depends on 1) The method of claim 1, wherein the an age-related condition, symptom or disease, comprises at least one condition, symptom or disease selected from the group consisting of skin conditions including wrinkles, hyperpigmentation, redness, rosacea, dryness, cracking, loss of firmness, loss of elasticity, thinning, loss of vibrance, wounds, scars, acne, sun damage, latent viral infection (e.g., to HSV, HPV) optionally in combination with an antiviral agent (e.g., docosanol, acyclovir, etc.), ulcers including diabetic ulcers, burns, atopic dermatitis, psoriasis, and hair loss or loss of hair coloration. ### Claim 20 (depends on 1) The method of claim 1, wherein the CBP/catenin antagonist is at least one selected from the group of compounds and salts thereof of Table 1, or another compound disclosed herein. ### Claim 21 (depends on 20) The method of claim 20, wherein the CBP/catenin antagonist comprises an alkyl and/or fatty acid ester derivative thereof as disclosed herein. ### Claim 22 (depends on 20) The method of claim 20, wherein the CBP/β-catenin antagonist comprises ICG-001 or an active alkyl and/or fatty acid ester derivative thereof as disclosed herein. ### Claim 23 (depends on 1) The method of claim 1, wherein administration of the CBP/β-catenin antagonist comprises at least of one topical, gingival, buccal, labial, vaginal, sub cutaneous, and oral administration. ### Claim 24 (depends on 20) The method claim 20, comprising co-administration of or adjunct treatment with at least one other therapeutic agent. ### Claim 25 (depends on 24) The method of claim 24, comprising simultaneously or adjunctively treating the subject with an anti-inflammatory agent or antiviral agent. ### Claim 26 (depends on 25) The method of claim 25, wherein said anti-inflammatory agent comprises a steroid or glucocorticoid steroid. ### Claim 27 (depends on 25) The method of claim 25, wherein the at least one anti-inflammatory agent is selected from the group consisting of: short-acting β2-agonists, long-acting β2-agonists, anticholinergics, corticosteroids, systemic corticosteroids, mast cell stabilizers, leukotriene modifiers, methylxanthines, β2-agonists, albuterol, levalbuterol, pirbuterol, artformoterol, formoterol, salmeterol, anticholinergics including ipratropium and tiotropium; corticosteroids including beclomethasone, budesonide, flunisolide, fluticasone, mometasone, triamcinolone, methyprednisolone, prednisolone, prednisone; leukotriene modifiers including montelukast, zafirlukast, and zileuton; mast cell stabilizers including cromolyn and nedocromil; methylxanthines including theophylline; combination drugs including ipratropium and albuterol, fluticasone and salmeterol, glucocorticoid steroids, budesonide and formoterol; antihistamines including hydroxyzine, diphenhydramine, loratadine, cetirizine, and hydrocortisone; immune system modulating drugs including tacrolimus and pimecrolimus; cyclosporine; azathioprine; mycophenolatemofetil; and combinations thereof. ### Claim 28 (depends on 20) The method of claim 20, wherein the one additional therapeutic agent is selected from the group consisting of anti-microbial agents, antifungal agents, and antibiotic agents. ### Claim 29 (depends on 28) The method of claim 28, wherein, the at least one additional therapeutic agent is selected from the group consisting of: ciclosporin, hyaluronic acid, carmellose, macrogol(s), dextran and hyprolose, sodium and calcium, sodium and povidone, hypromellose, carbomer, amikacin, gentamicin, kanamycin, neomycin, netilmicin, streptomycin, tobramycin, paromomycin, geldanamycin, herimycin, loracarbef, ertapenem, imipenem/cilastatin, meropenem, cefadroxil, cefazolin, cefalotin/cefalothin, cephalexin, cefaclor, cefamandole, cefoxitin, cefuroxime, cefixime, cefdinir, cefditoren, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, cefeprime, teicoplanin, vancomycin, azithromycin, clarithromycin, dirithromycin, erythromycin, roxithromycin, troleandomycin, telithromycin, spectinomycin, aztreonam, amoxicillin, ampicillin, azlocillin, carbenicillin, cloxacillin, dicloxacillin, flucloxacillin, mezlocillin, nafcillin, penicillin, peperacillin, ticarcillin, bacitracin, colistin, polymyxin B, ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, trovafloxacin, mafenide, protosil, sulfacetamide, sulfamethizole, sulfanilamide, sulfasalazine, sulfisoxazole, trimethoprim, trimethoprim-sulfamethoxazole, demeclocycline, doxycycline, minocycline, oxytetracycline, tetracycline, arsphenamine, chloramphenicol, clindamycin, lincoamycin, ethambutol, fosfomycin, fusidic acid, furazolidone, isoniazid, linezolid, metronidazole, mupirocin, nitrofurantoin, platensimycin, pyrazinamide, quinupristin/dalfopristin, rifampin/rifampicin, tinidazole, miconazole, ketoconazole, clotrimazole, econazole, bifonazole, butoconazole, fenticonazole, isoconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, fluconazole, itraconazole, isavuconazole, ravuconazole, posaconazole, voriconazole, teronazole, terbinafine, amorolfine, naftifine, butenafine, anidulafungin, caspofungin, micafungin, ciclopirox, flucytosine, griseofulvin, Gentian violet, haloprogin, tolnaftate, undecylenic acid, and combinations thereof. ### Claim 30 A method for stimulating hair growth, regrowth or pigmentation, comprising administering to a subject in need thereof an amount of a CBP/catenin antagonist sufficient for stimulating at least one of hair growth, regrowth, and pigmentation. ### Claim 31 (depends on 30) The method of claim 30, comprising administering the CBP/catenin antagonist in a manner and amount sufficient to provide for increasing the number of asymmetric renewing divisions relative to, or at the expense of symmetric divisions of somatic follicular stem cells, wherein at least one of hair growth, regrowth, thickening, lengthening and pigmentation is afforded. ### Claim 32 (depends on 30) The method of claim 30, wherein the CBP/catenin antagonist is present in an amount sufficient to modulate or increase the expression of an adenosine receptor in dermal cells (e.g., dermal papilla cells). ### Claim 33 (depends on 32) The method of claim 32, wherein the adenosine receptor is at least one selected from A1, A2A, and A2B. ### Claim 34 (depends on 30) The method of claim 30, wherein the CBP/catenin antagonist is present in an amount sufficient to modulate or increase the expression of sulfonylurea receptor 2B in dermal papilla cells. ### Claim 35 (depends on 30) The method of claim 30, wherein the CBP/catenin antagonist is at least one selected from the group of compounds and salts thereof encompassed by Table 1 or otherwise disclosed herein. ### Claim 36 (depends on 35) The method of claim 35, wherein the CBP/catenin antagonist comprises an alkyl and/or fatty acid ester derivative thereof as disclosed herein. ### Claim 37 (depends on 35) The method of claim 35, wherein the CBP/catenin antagonist comprises ICG-001 or an active alkyl and/or fatty acid ester derivative thereof as disclosed herein. ### Claim 38 (depends on 30) The method of claim 30, wherein administration of the CBP/β-catenin antagonist comprises at least of one topical, sub cutaneous, and oral administration. ### Claim 39 (depends on 38) The method of claim 38, comprising co-administration of or adjunct treatment with at least one other hair growth stimulating agent, or hair loss preventing agent. ### Claim 40 (depends on 39) The method of claim 39, wherein the at least one other hair growth stimulating agent is at least one selected from the group consisting of minoxidil, finasteride, dutasteride, bimatoprost and antiandrogen receptor blockers including fluridil. ### Claim 41 (depends on 39) The method of claim 39, comprising co-administration of or adjunct treatment with at least one anti-inflammatory agent. ### Claim 42 (depends on 41) The method of claim 41, wherein the at least one anti-inflammatory agent is selected from the group consisting of: short-acting β2-agonists, long-acting β2-agonists, anticholinergics, corticosteroids, systemic corticosteroids, mast cell stabilizers, leukotriene modifiers, methylxanthines, β2-agonists, albuterol, levalbuterol, pirbuterol, artformoterol, formoterol, salmeterol, anticholinergics including ipratropium and tiotropium; corticosteroids including beclomethasone, budesonide, flunisolide, fluticasone, mometasone, triamcinolone, methyprednisolone, prednisolone, prednisone; leukotriene modifiers including montelukast, zafirlukast, and zileuton; mast cell stabilizers including cromolyn and nedocromil; methylxanthines including theophylline; combination drugs including ipratropium and albuterol, fluticasone and salmeterol, glucocorticoid steroids, budesonide and formoterol; antihistamines including hydroxyzine, diphenhydramine, loratadine, cetirizine, and hydrocortisone; immune system modulating drugs including tacrolimus and pimecrolimus; cyclosporine; azathioprine; mycophenolatemofetil; and combinations thereof. ### Claim 43 A method for increasing the expression of an adenosine receptor in dermal cells, comprising administering to a subject in need thereof an amount of a CBP/catenin antagonist sufficient for increase the expression of an adenosine receptor in dermal cells, preferably dermal papilla cells. ### Claim 44 (depends on 43) The method of claim 43, wherein the adenosine receptor is at least one selected from A1, A2A, and A2B. ### Claim 45 (depends on 43) The method of claim 43, wherein the CBP/catenin antagonist is present in an amount sufficient to modulate or increase the expression of sulfonylurea receptor 2B in dermal papilla cells. ### Claim 46 (depends on 43) The method of claim 43, wherein the CBP/catenin antagonist is at least one selected from the group of compounds or salts thereof encompassed by Table 1 or otherwise disclosed herein. ### Claim 47 (depends on 46) The method of claim 46, wherein the CBP/catenin antagonist comprises an active alkyl and/or fatty acid ester derivative thereof. ### Claim 48 (depends on 46) The method of claim 46, wherein the CBP/catenin antagonist comprises ICG-001 or an active alkyl and/or fatty acid ester derivative thereof. ### Claim 49 (depends on 43) The method of claim 43, wherein administration of the CBP/catenin antagonist comprises at least of one topical, sub cutaneous, and oral administration. ### Claim 50 A method for treating a condition or disease of the skin or at least one symptom thereof, comprising administering to a subject in need thereof an amount of a CBP/β-catenin antagonist sufficient for treating a condition or disease of the skin or at least one symptom thereof. ### Claim 51 (depends on 50) The method of claim 50, comprising administering the CBP/catenin antagonist in a manner and amount sufficient to provide for increasing the number of asymmetric renewing divisions relative to, or at the expense of symmetric divisions of somatic skin stem cells, wherein treating a condition or disease of the skin or at least one symptom thereof is afforded. ### Claim 52 (depends on 50) The method of claim 50, wherein the condition or disease of the skin, comprises at least one condition or disease selected from the group consisting of wounds, scars, acne, sun damage, latent viral infection (e.g., to HSV, HPV), ulcers including diabetic ulcers, burns, atopic dermatitis, psoriasis, and effects of aging including wrinkles, hyperpigmentation, redness, rosacea, dryness, cracking, loss of firmness, loss of elasticity, thinning, and loss of vibrance. ### Claim 53 (depends on 50) The method of claim 50, wherein the CBP/catenin antagonist is at least one selected from the group of compounds and salts thereof encompassed by Table 1 or otherwise disclosed herein. ### Claim 54 (depends on 53) The method of claim 53, wherein the CBP/catenin antagonist comprises an alkyl and/or fatty acid ester derivative thereof as disclosed herein. ### Claim 55 (depends on 53) The method of claim 53, wherein the CBP/catenin antagonist comprises ICG-001 or an active alkyl and/or fatty acid ester derivative thereof as disclosed herein. ### Claim 56 (depends on 50) The method of claim 50, wherein administration of the CBP/catenin antagonist comprises at least of one topical, gingival, buccal, sub cutaneous, and oral administration. ### Claim 57 (depends on 53) The method of claim 53, comprising co-administration of or adjunct treatment with at least one other therapeutic agent. ### Claim 58 (depends on 57) The method of claim 57, comprising simultaneously or adjunctively treating the subject with an anti-inflammatory agent. ### Claim 59 (depends on 58) The method of claim 58, wherein said anti-inflammatory agent comprises a steroid or glucocorticoid steroid. ### Claim 60 (depends on 58) The method of claim 58, wherein the at least one anti-inflammatory agent is selected from the group consisting of: short-acting β2-agonists, long-acting β2-agonists, anticholinergics, corticosteroids, systemic corticosteroids, mast cell stabilizers, leukotriene modifiers, methylxanthines, β2-agonists, albuterol, levalbuterol, pirbuterol, artformoterol, formoterol, salmeterol, anticholinergics including ipratropium and tiotropium; corticosteroids including beclomethasone, budesonide, flunisolide, fluticasone, mometasone, triamcinolone, methyprednisolone, prednisolone, prednisone; leukotriene modifiers including montelukast, zafirlukast, and zileuton; mast cell stabilizers including cromolyn and nedocromil; methylxanthines including theophylline; combination drugs including ipratropium and albuterol, fluticasone and salmeterol, glucocorticoid steroids, budesonide and formoterol; antihistamines including hydroxyzine, diphenhydramine, loratadine, cetirizine, and hydrocortisone; immune system modulating drugs including tacrolimus and pimecrolimus; cyclosporine; azathioprine; mycophenolatemofetil; and combinations thereof. ### Claim 61 (depends on 57) The method of claim 57, wherein the one additional therapeutic agent is selected from the group consisting of anti-microbial agents, antifungal agents, and antibiotic agents. ### Claim 62 (depends on 61) The method of claim 61, wherein, the at least one additional therapeutic agent is selected from the group consisting of: ciclosporin, hyaluronic acid, carmellose, macrogol(s), dextran and hyprolose, sodium and calcium, sodium and povidone, hypromellose, carbomer, amikacin, gentamicin, kanamycin, neomycin, netilmicin, streptomycin, tobramycin, paromomycin, geldanamycin, herimycin, loracarbef, ertapenem, imipenem/cilastatin, meropenem, cefadroxil, cefazolin, cefalotin/cefalothin, cephalexin, cefaclor, cefamandole, cefoxitin, cefuroxime, cefixime, cefdinir, cefditoren, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, cefeprime, teicoplanin, vancomycin, azithromycin, clarithromycin, dirithromycin, erythromycin, roxithromycin, troleandomycin, telithromycin, spectinomycin, aztreonam, amoxicillin, ampicillin, azlocillin, carbenicillin, cloxacillin, dicloxacillin, flucloxacillin, mezlocillin, nafcillin, penicillin, peperacillin, ticarcillin, bacitracin, colistin, polymyxin B, ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, trovafloxacin, mafenide, protosil, sulfacetamide, sulfamethizole, sulfanilamide, sulfasalazine, sulfisoxazole, trimethoprim, trimethoprim-sulfamethoxazole, demeclocycline, doxycycline, minocycline, oxytetracycline, tetracycline, arsphenamine, chloramphenicol, clindamycin, lincoamycin, ethambutol, fosfomycin, fusidic acid, furazolidone, isoniazid, linezolid, metronidazole, mupirocin, nitrofurantoin, platensimycin, pyrazinamide, quinupristin/dalfopristin, rifampin/rifampicin, tinidazole, miconazole, ketoconazole, clotrimazole, econazole, bifonazole, butoconazole, fenticonazole, isoconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, fluconazole, itraconazole, isavuconazole, ravuconazole, posaconazole, voriconazole, teronazole, terbinafine, amorolfine, naftifine, butenafine, anidulafungin, caspofungin, micafungin, ciclopirox, flucytosine, griseofulvin, Gentian violet, haloprogin, tolnaftate, undecylenic acid, and combinations thereof. ### Claim 63 (depends on 52) The method of claim 52, comprising treating a wound to decrease scarring in the wound to the surface tissue, wherein scarring is reduced. ### Claim 64 (depends on 52) The method of claim 52, wherein treating comprises accelerating epidermal or dermal layering. ### Claim 65 (depends on 52) The method of claim 52, wherein treating increases cellular migration of at least one type of cell to the wound. ### Claim 66 (depends on 65) The method of claim 65, wherein the type of cellular migration or proliferation comprises at least one cell selected from the group consisting of: keratinocytes, fibroblasts, epidermal cells, dermal cells, epithelial cells, mast cells, neutrophils, lymphocytes, and macrophages. ### Claim 67 (depends on 52) The method of claim 52, wherein treating accelerates neoangiogenesis of blood vessels or lymphatic vessels. ### Claim 68 (depends on 52) The method of claim 52, wherein treating increases collagen deposition at the wound. ### Claim 69 (depends on 52) The method of claim 52, comprising treating a wound to a surface tissue or a symptom thereof of at least one wound type selected from the group consisting of lacerations, abrasions, rupture, puncture wounds, chemical, thermal, or radiation-induced burns, cuts, scrapes, incisions, blisters, diabetic ulcers, bedsores or pressure ulcers, skin grafts, and surgical wounds. ### Claim 70 A method for cosmetically treating a condition of the skin or at least one symptom thereof, comprising administering to a subject in need thereof an amount of a CBP/catenin antagonist sufficient for cosmetically treating a condition of the skin or at least one symptom thereof. ### Claim 71 (depends on 70) The method of claim 70, comprising administering the CBP/catenin antagonist in a manner and amount sufficient to provide for increasing the number of asymmetric renewing divisions relative to, or at the expense of symmetric divisions of somatic skin stem cells, cosmetically treating a condition of the skin or at least one symptom thereof is afforded. ### Claim 72 (depends on 70) The method of claim 70, wherein a condition of the skin, comprises treating at least one condition or disease selected from the group consisting of wrinkles, scarring, hyperpigmentation, redness, rosacea, dryness, cracking, loss of firmness, loss of elasticity, thinning, and loss of vibrance. ### Claim 73 (depends on 70) The method of claim 70, wherein the CBP/catenin antagonist is at least one selected from the group of compounds and salts thereof encompassed by Table 1 or otherwise disclosed herein. ### Claim 74 (depends on 73) The method of claim 73, wherein the CBP/catenin antagonist comprises an alkyl and/or fatty acid ester derivative thereof as disclosed herein. ### Claim 75 (depends on 73) The method of claim 73, wherein the CBP/catenin antagonist comprises ICG-001 or an active alkyl and/or fatty acid ester derivative thereof as disclosed herein. ### Claim 76 (depends on 70) The method of claim 70, wherein administration of the CBP/β-catenin antagonist comprises at least of one topical, gingival, buccal, sub cutaneous, and oral administration.